Bleeds in Triple Therapy May Hinge on Drug Choice (CME/CE)
(MedPage Today) -- Substituting prasugrel (Effient) for clopidogrel (Plavix) in stented patients on triple therapy may increase the risk of bleeding, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 21, 2013 Category: Cardiology Source Type: news
ACC: Extra-Long Plavix Course No Help After Stenting (CME/CE)
SAN FRANCISCO (MedPage Today) -- Extra-extended dual antiplatelet therapy after placement of a drug-eluting stent won't boost outcomes, Korean researchers affirmed in the DES-LATE trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 16, 2013 Category: Cardiology Source Type: news
Clopidogrel/atorvastatin protect in carotid stenting
A 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin provided neuroprotection in patients undergoing carotid stenting. (Source: theHeart.org)
Source: theHeart.org - March 14, 2013 Category: Cardiology Source Type: news
Clot Buster Safe for Stroke Patients on Blood Thinners
Fears that giving tPA to those taking aspirin or Plavix might raise risk of brain bleeds largely unfounded, researchers say
Source: HealthDay
Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 14, 2013 Category: Consumer Health News Source Type: news
Clopidogrel/Atorvastatin Protect in Carotid StentingClopidogrel/Atorvastatin Protect in Carotid Stenting
A 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin provided neuroprotection in patients undergoing carotid stenting. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
ACC: Statin Plus Plavix Aids in Carotid Stenting (CME/CE)
SAN FRANCISCO (MedPage Today) -- A higher loading dose of clopidogrel (Plavix) along with a reload of atorvastatin (Lipitor) was neuroprotective in patients having carotid stenting, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2013 Category: Cardiology Source Type: news
No Stent Thrombosis Seen When Plavix and Aspirin Stopped Early
Important news for stent patients and cardiologists alike: data from a new analysis of Medtronic's (NYSE: MDT) RESOLUTE drug-eluting stent program show very low occurrence of stent thrombosis when dual antiplatelet therapy (DAPT) is interrupted or discontinued after one month. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 14, 2013 Category: Cardiology Source Type: news
Cangrelor, New Anti-Clotting Drug More Effective Than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine. Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news
Effect of platelet inhibition with cangrelor during PCI on ischaemic events
Source: New England Journal of Medicine
Area: News
The findings of a study evaluating whether cangrelor reduces ischaemic complications of percutaneous coronary intervention (PCI) have been presented at the meeting of the American College of Cardiology and published early online in the New England Journal of Medicine.
The authors note that thrombotic complications during PCI remain a major concern, despite advances in adjunctive pharmacotherapy. Although platelet adenosine diphosphate (ADP) P2Y12 inhibitors reduce the risk of ischaemic events, particularly stent thrombosis, only oral agents are currently availa...
Source: NeLM - Cardiovascular Medicine - March 11, 2013 Category: Cardiology Source Type: news
Cangrelor Cuts Complications at PCI vs ClopidogrelCangrelor Cuts Complications at PCI vs Clopidogrel
PCI indication didn't matter: the risk of periprocedural complications like MI or stent thrombosis fell with the newer ADP-receptor blocker, given intravenously, compared with oral clopidogrel. Whether bleeding risks were similar depended on how bleeding is defined. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 11, 2013 Category: Cardiology Tags: Cardiology News Source Type: news
Blood Thinner Shows Benefit
Medicines Co.'s anticlotting drug, Cangrelor, significantly outperformed the widely used medicine clopidogrel in heart patients getting stents. The results follow two earlier studies that failed to show a benefit. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
Plavix Disclosures are Probed
The U.S. Justice Department is investigating disclosures to the FDA about the variability in patient responses to the blood-thinning drug Plavix, according to Sanofi, one of the drug's co-marketers. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
Medicines Co's Cangrelor clearly tops Plavix in pivotal trial
SAN FRANCISCO (Reuters) - The Medicines Co's experimental intravenous blood clot preventer Cangrelor, which is intended for use during angioplasty procedures, solidly outperformed commonly used Plavix in a pivotal late stage study, likely resurrecting the drug's prospects. (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Cangrelor cuts complications at PCI vs clopidogrel in CHAMPION-PHOENIX; bleeding a caution
PCI indication didn't matter: the risk of periprocedural complications like MI or stent thrombosis fell with the newer ADP-receptor blocker, given intravenously, compared with oral clopidogrel. Whether bleeding risks were similar depended on how bleeding is defined. (Source: theHeart.org)
Source: theHeart.org - March 10, 2013 Category: Cardiology Source Type: news
ACC: Novel IV Agent 'CHAMPION' Antiplatelet (CME/CE)
SAN FRANCISCO (MedPage Today) -- The novel fast-acting antiplatelet agent cangrelor given at the time of percutaneous coronary intervention (PCI) cuts ischemic complications better than clopidogrel (Plavix), the CHAMPION PHOENIX trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 10, 2013 Category: Cardiology Source Type: news
